10-Q/A: Zynex Reports Steep Revenue Decline and Net Loss Amid TriCare Payment Suspension and Class Action Lawsuit

Zynex, Inc. reported a significant 43% drop in net revenue and a net loss of $10.4 million for Q1 2025, primarily driven by a temporary payment suspension from TriCare and a class action lawsuit alleging securities fraud.

Summary

• Net revenue for the three months ended March 31, 2025, decreased by 43% to $26.6 million, down from $46.5 million in the same period of 2024.
• The company reported a net loss of $10.4 million for Q1 2025, a significant decline from a net income of $10,000 in Q1 2024.
• Cash used in operating activities was $10.5 million for Q1 2025, compared to cash provided by operating activities of $2.1 million in Q1 2024.
• TriCare, a government payer representing 20-25% of annual revenue, temporarily suspended payments due to allegations of misrepresentation of supplies and equipment, diagnosis justification, and lack of physician orders for supply replenishment.
• Zynex recognized only $2.2 million in revenue from TriCare for Q1 2025, matching cash received, and fully reserved all other fulfillments and related revenue for the period, resulting in no TriCare receivables as of March 31, 2025.
• A staff reduction of approximately 15% (primarily corporate departments) and other expense reductions are expected to result in annual savings of approximately $35 million.
• Device orders decreased by 3% for the three months ended March 31, 2025, compared to the same period in 2024.
• The company purchased 1,700,000 shares of its common stock from CEO Thomas Sandgaard for $4.9 million at a price of $2.905 per share on March 13, 2025.
• Working capital decreased to $40.1 million as of March 31, 2025, from $58.3 million as of December 31, 2024.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to a substantial decline in revenue and a significant net loss, coupled with a major customer (TriCare) payment suspension and an ongoing class action lawsuit. The identified material weakness in internal controls and the looming convertible note maturity further exacerbate the negative outlook, despite some cost-saving measures.

Positives

• Management implemented a staff reduction of approximately 15% and other expense reductions, projected to yield annual savings of $35 million.
• The company believes it had good evidence to get TriCare payments reinstated following an April 2025 meeting, despite the continued suspension.
• The Board of Directors approved the purchase of shares from the CEO, believing the company's stock is undervalued and the cash use is appropriate.

Negatives

• Net revenue decreased by 43% to $26.6 million in Q1 2025, primarily due to the TriCare payment suspension and a 3% decline in device orders.
• The company reported a net loss of $10.4 million for Q1 2025, a significant reversal from a net income of $10,000 in Q1 2024.
• Cash used in operating activities was $10.5 million in Q1 2025, indicating a negative cash flow from core operations.
• The temporary payment suspension by TriCare, a major government payer, significantly impacted revenue and cash collections, with the suspension continuing as of June 2025.
• Supplies revenue decreased by 55% to $14.7 million, largely due to the TriCare suspension and a smaller patient base from slowing order growth.
• Cost of revenue as a percentage of revenue increased to 31% in Q1 2025 from 20% in Q1 2024 due to decreased revenue.
• Sales and marketing expense as a percentage of revenue increased to 64% in Q1 2025 from 50% in Q1 2024, despite a decrease in absolute spending.
• General and administrative expense as a percentage of revenue increased to 54% in Q1 2025 from 29% in Q1 2024, partly due to increased professional fees and decreased revenue.

Risks

• The temporary payment suspension by TriCare could harm the company's reputation and continue to adversely impact revenues and profits, potentially leading to increased scrutiny.
• A material weakness in Information Technology General Controls (ITGCs) was identified, indicating that controls were not effectively designed and operating to ensure IT program and data changes affecting financial applications are identified, tested, authorized, and implemented appropriately.
• The company's $60 million convertible senior notes mature on May 15, 2026, and current cash balance and operating cash flows are not sufficient to redeem them, requiring creditor consent or refinancing, with no assurance of favorable terms or ability to refinance.
• A putative class action lawsuit was filed on March 20, 2025, alleging securities fraud, misrepresentation of supplies and equipment, inflated revenue, and concealed false claims that drew insurer scrutiny and potential government penalties.
• New duties, tariffs, trade barriers, and retaliatory countermeasures implemented by the U.S. and other governments could increase costs of manufactured products and components sourced outside the U.S., reducing gross margins.
• Changes in U.S. and foreign trade policies and uncertainty about such changes can lead to increased market volatility and currency exchange rate fluctuations, making it difficult to predict business impact.

Future Outlook

Management believes that current cash and cash equivalents, combined with anticipated cash flow from operations, will be sufficient to meet working capital and capital expenditure requirements for at least the next twelve months. However, the company's $60 million outstanding convertible senior notes mature on May 15, 2026, and current cash and operating cash flows are not sufficient to redeem them, making redemption contingent on obtaining creditor consent or refinancing the agreement. There is no assurance that favorable terms will be secured or that refinancing will be possible, which could materially adversely impact operations.

Management Comments

• We held a meeting with TriCare in April 2025 and believe we had good evidence to get payments reinstated.
• Due to the temporary payment suspension and lack of clarity on the timing of a resolution, we restructured our staff to align with current revenue.
• The staff reduction along with other expense reductions made during the second half of 2024 and the first quarter of 2025 will result in savings of approximately $35 million annually.
• The disinterested Board and Audit Committee Members deemed it to be in the best interest of the Company to purchase the shares from Mr. Sandgaard as they believe the current market price for the Company's stock is undervalued and the Company's cash position is such that the purchase of shares is a good use of funds.

Industry Context

The medical device industry, particularly in electrotherapy and pain management, is heavily reliant on third-party payer reimbursement. Zynex's significant revenue concentration with TriCare (20-25% of annual revenue) highlights the vulnerability to changes in payer policies or disputes. The allegations of misrepresentation and subsequent payment suspension by a major government payer like TriCare could signal increased regulatory scrutiny across the industry regarding billing practices and medical necessity for devices and supplies. The company's efforts to develop new products like fluid monitoring systems and laser-based oximeters (NiCO and HemeOx) indicate a strategic move towards diversification within patient monitoring, though these products are still awaiting FDA clearance.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess Zynex's performance against global benchmarks. Therefore, a direct comparison to industry standards based solely on the provided content is not feasible.

Management Changes

Corporate Governance

Legal Proceedings

• On March 20, 2025, a putative Zynex shareholder filed a securities fraud class action lawsuit (Tuncel v. Zynex Inc. et al., No. 25-cv-913) in the U.S. District Court for the District of Colorado.
• The complaint alleges that Zynex and its CEO/CFO failed to disclose material adverse facts, including an oversupply scheme, inflated revenue, and concealed false claims that drew scrutiny from insurers, potentially leading to adverse consequences like removal from insurance networks and federal penalties.
• The lawsuit seeks class certification and unspecified damages.

Related Party Transactions

• On March 13, 2025, the disinterested Board and Audit Committee approved the purchase of 1,700,000 common shares of ZYXI from Thomas Sandgaard, Chairman, President, Chief Executive Officer, and Principal Executive Officer, at the closing market price of $2.905 per share, totaling $4,938,500.

Stakeholder Impact

• Shareholders: Significant decline in revenue and net loss, coupled with a class action lawsuit and ongoing TriCare payment suspension, could lead to further share price depreciation and increased uncertainty.
• Employees: Approximately 15% of staff, primarily in corporate departments, were reduced, impacting employment.
• Customers (Patients): The company continues to support both existing and new TriCare patients by fulfilling prescriptions despite the payment suspension, aiming to maintain service continuity.
• Creditors (Convertible Note Holders): The company's inability to redeem the $60 million convertible notes with current cash flows by May 2026 creates uncertainty regarding repayment, potentially requiring negotiation or refinancing.
• Suppliers: The company sourced approximately 68% of electrotherapy product supplies from four significant vendors in Q1 2025, indicating continued reliance on key suppliers despite reduced orders.

Next Steps

• Continue efforts to resolve the temporary payment suspension with TriCare and seek reinstatement of payments.
• Implement and complete remediation plans to address the identified material weakness in Information Technology General Controls (ITGCs).
• Engage counsel to represent the company and individual defendants in the putative securities fraud class action lawsuit.
• Address the upcoming maturity of the $60 million convertible senior notes by seeking creditor consent, termination, amendment, or refinancing of the agreement.

Key Dates

Recommendation

The filing reveals a severe deterioration in Zynex's financial performance, marked by a 43% revenue decline and a substantial net loss, primarily due to the ongoing TriCare payment suspension. This suspension, affecting a significant portion of annual revenue, introduces immense uncertainty and operational risk. Furthermore, the company faces a securities fraud class action lawsuit and has identified a material weakness in its internal controls. The looming maturity of $60 million in convertible notes, which the company cannot currently redeem, adds significant liquidity concerns. While cost-cutting measures are in place, the magnitude of the negative financial trends and the accumulation of severe operational and legal challenges outweigh any positive aspects, indicating a high probability of continued financial distress and potential further share price decline. A seasoned investor would likely divest to mitigate exposure to these compounding risks.

Keywords

Medical devices, Electrotherapy, Pain management, SEC filing, Quarterly report, Financial results, Revenue decline, Net loss, TriCare, Payment suspension, Class action lawsuit, Corporate governance, Risk factors, Liquidity, Convertible notes, Stock repurchase, Internal controls, ZYXI